A new method of antitumor therapy with a high dose of TNF perfusion for unresectable liver tumors

Anticancer Research

Volumn 20, Issue 6 A, 2000, Pages 4087-4096

  Nakamoto, T ^a   Inagawa, H ^a   Takagi, K ^a   Soma, G I ^a  

^a TAKANO HOSPITAL   (Japan)

Author keywords

Isolated hepatic perfusion; Isolated hypoxic hepatic perfusion; Melphalan; TNF SAM2; Unresectable liver tumor

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CISPLATIN; DEXAMETHASONE; FLUOROURACIL; LACTATE DEHYDROGENASE; LIPOPOLYSACCHARIDE; MELPHALAN; MITOMYCIN C; RECOMBINANT MUTANT HUMAN TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MEGADOSE; HUMAN; HYPOTENSION; LD 50; LEUKOPENIA; LIVER CARCINOMA; LIVER TOXICITY; MELANOMA; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; THROMBOSIS;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033636080     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (74)

1. Tumors of the liver
2. Neoplasms of the liver
3. Early recognition of hepatocellular carcinoma
4. The natural history of hepatocellular carcinoma. A study of 100 unresected cases
5. A chemotherapeutic approach to colorectal carcinoma
6. Clinical perspective of human colorectal cancer metastasis
7. Prognostic factors for survival and disease-free survival in hepatic metastases from colorectal cancer treated by resection
8. Treatment of cancer of the liver. Twenty years' experience with infusion and resection in 414 patients
9. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma
10. A prospective randomized trial of regional versus systemic continuous 5-fluoro-deoxyuridine chemotherapy in the treatment of colorectal liver metastases
11. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: The Northern California Oncology Group Tria
12. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metatases from colorectal cancer. A randomized trial
13. An endotoxin-induced serum factor that causes necrosis of tumors
14. Effect of tumor necrosis factor on cultured human melanoma cells
15. Cell death induction by receptors of the TNF family: Towards a molecular understanding
16. A phase I study of recombinant human tumor necrosis factor
17. Phase I studies of rTNF-α in patients with advanced cancer
18. Tumor necrosis factor in man: Clinical and biological observations
19. Recombinant human necrosis factor-α: Thrombus formation is a cause of anti-tumor activity
20. Anti-tumour therapy by induction of endogenous tumour necrosis factor
21. Study of tumor necrosis effects by the endogenous tumor necrosis factor (TNF) induction method
22. Endogenous production of tumor necrosis factor in normal mice and human cancer patients by interferons and other cytokines combined with biological response modifers of bacterial origin
23. Collective results of 44 patients with recurrent and/or advanced cancer treated by endogenous TNF inducing therapy or EET (endogenous/exogenous TNF) therapy
24. Clinical results of EET (exogenous/endogenous TNF) therapy on colorectal cancer
25. Intratumoral tumor necrosis factor induction in tumor-bearing mice by exogenous/endogenous tumor necrosis factor therapy as compared with systemic administration of various biologic response modifiers
26. Anti-tumor therapy to metastatic and recurrent colorectal carcinoma by novel recombinant TNF
27. Clinical experience with high-dose tumor necrosis factor alpha in regional therapy of advanced melanoma
28. Synergistic antitumor effects of immunotherapy with rconmbinant interleukin-2 and recombinant tumor necrosis factor-α
29. Early endothelium activation and polymorphonuclear cell invasion preceede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNFα)
30. VWF release and platelet aggregation in human melanoma after perfusion with TNF-α
31. Transient induction of E-selectin expression following TNF-based isolated limb perfusion in melanoma and sarcoma patients is not tumor specific
32. Toxic Effect of Tumor Necrosis Factor on Tumor Vasculature in Mice
33. Angiographic observations before and after high dose TNF isolated limb perfusion in patients with extremity soft tissue sarcomas
34. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver
35. Isolated hepatic perfusion in the pig with TNF-α with and without melphalan
36. Isolated hypoxic hepatic perfusion with tumor nectosis factor-alpha, melphalan and mitomycin C using balloon catheter techniques a pharmaco-kinetic study in pigs
37. Pharmacokinetics of isolated hepatic perfusion with high dose tumor necrosis factor in rat model
38. Isolated lung perfuion with tumor necrosis factor: A swine model in preparation of human trials
39. Isolated lung perfusion with tumor necrosis factor for pulmonary metastases
40. Tumor necrosis factor-α(TNFα) in isolated kidney perfusion in rats: Toxicity and antitumor effects
41. A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients
42. A phase I clinical trial of recombinant human tumor necrosis factor
43. Recombinant tumour necrosis factor alpha administered subcutaneously or intramuscularly for treatment of advanced malignant disease: A phase I trial
44. Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites
45. Tumor necrosis factor
46. Biological activity of novel recombinant tumor necrosis factor having N-terminal amino acid sequences derived from cytokine factors produced by THP-1 cells
47. Antitumor effect of systemic administration of novel recombinant tumor necrosis factor (rTNF-S) with less toxicity than conventional rTNF-α in vivo
48. Predominance of rTNF-SAM2 with higher therapeutic index than conventional TNF-α is ascribed to the style of oligomer
49. Hemodynamic evaluation of recombinant human tumor necrosis factor (TNF)-alpha, TNF-SAM2 and liposomal TNF-SAM2 in an anesthetized dog model
50. Regional therapy of melanoma
51. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma
52. Isolated limb perfusion with high-dose tumor necrosis factor-α in combination with interferon-γ and melphalan for nonresectable extremity soft tissue sarcomas: A multicenter trial
53. Administration of high-dose tumor necrosis factor alpha by isolation perfusion of the limbs. Rationale and results
54. TNF registered in Europe for ILP in extremity sarcoma treatment: New findings from the lab explain efficacy and indicate new role for TNF in systemic treatment modalities
55. High serum levels of TNF-α after its administration for isolation perfusion of the limb
56. Dual role of tumor necrosis factor-α in angiogenesis
57. Evidence for the involvement of endothelial cell integrin αVb3 in the disruption of the tumor vasculature induced by TNF and IFN-γ
58. Synergistic antitumor effects of TNF-α and melphalan in an isolated limb perfusion model of rat sarcoma: A histopathologic, immuno-histochemical and electron microscopic study
59. High dose tumor necrosis factor-α and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90 % response rate and limb preservation
60. Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability
61. Augmentation for intra-tumoral accumulation and anti-tumor activity of liposome-encapsulated adriamycin by tumor necrosis factor-alpha in mice
62. Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts
63. Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor-independent mechanisms
64. Isolated limb perfusion using TNF-SAM2 in combination with melphalan and doxorubicin in rats
65. In vivo isolated liver perfusion technique in a rat hepatic metastasis model: 5-fluorouracil concentrations in tumor tissue
66. Reduction of hepato-toxicity of tumor necrosis factor in isolated hepatic perfusion by administration of glucocorticoid as well as lipopolysaccharide
67. Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: Experimental studies in pigs and phase I data from humans
68. First experience and technical aspects of isolated liver perfusion for extensive liver metastasis
69. Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia, tumour necrosis factor alpha and melphalan
70. TNFα in isolated perfusion systems: Success in the limb, developments for the liver credits, debits and future perspectives
71. Hepatic arterial infusion chemotherapy with continuous low dose administration of cisplatin and 5-fluorouracil for multiple recurrence of hepatocellular carcinoma after surgical treatment
72. Dormancy of microme-tastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
73. A long-term survivor case of malignant mesothelioma treated by recombinant tumor necrosis factor-SAM2 (TNF-α Mutein) and 5-fluorouracil (5-FU): A new therapeutic approach based of host-tumor relationship
74. Laparoscopic surgery